1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Aminoacyl-tRNA Synthetase

Aminoacyl-tRNA Synthetase

Aminoacyl-tRNA synthetases (AARSs) are the enzymes that catalyze the aminoacylation reaction by covalently linking an amino acid to its cognate tRNA in the first step of protein translation. In mammals, AARSs usually exist in free form or in the form of a multi-tRNA synthetase complex (MSC), and the latter consists of eight AARSs and three non-enzymatic AARS-interacting multi-functional proteins (AIMP1/p43, AIMP2/p38, and AIMP3/p18).

AARSs are responsible for the proper pairing of codons on mRNA with amino acids. AARSs are also involved in RNA splicing, transcriptional regulation, translation, and other aspects of cellular homeostasis. Study of these enzymes is of great interest to the researchers due to its pivotal role in the growth and survival of an organism. AARSs are one of the leading targets for developing novel anti-infective agents. Further, unfolding the interesting structural and functional aspects of these enzymes in the last few years has qualified them as a potential drug target against various diseases.

Aminoacyl-tRNA Synthetase Related Products (11):

Cat. No. Product Name Effect Purity
  • HY-112862
    Arg-AMS
    Inhibitor ≥98.0%
    Arg-AMS is a potent nanomolar inhibitor of arginyl tRNA synthetase, which displays tightly bound inhibitory characteristics for the A-domains in non-ribosomal peptide synthetases (NRPS) enzymes.
  • HY-112860
    Asp-AMS
    Inhibitor
    Asp-AMS, an analogue of aspartyl-adenylate, is an aspartyl-tRNA synthetase inhibitor and also a strong competitive inhibitor of the mitochondrial enzyme.
  • HY-108939
    Aminoacyl tRNA synthetase-IN-1
    Inhibitor 99.63%
    Aminoacyl tRNA synthetase-IN-1 is a bacterial aminoacyl tRNA synthetase (aaRS) inhibitor.
  • HY-112861A
    Gln-AMS TFA
    Inhibitor
    Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor. Gln-AMS inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 µM.
  • HY-108940
    GlyRS-IN-1
    Inhibitor
    GlyRS-IN-1 is a glycyl-tRNA synthase (GlyRS) inhibitor extracted from patent WO 2017066459 A1. GlyRS-IN-1 can also inhibit the growth of bacteria.
  • HY-126130
    LysRs-IN-2
    Inhibitor 98.69%
    LysRs-IN-2 is a lysyl-tRNA synthetase (KRS) inhibitor with IC50s of 0.015 μM and 0.13 μM for Plasmodium falciparum lysyl-tRNA synthetase (PfKRS) and Cryptosporidium parvum lysyl-tRNA synthetase (CpKRS), respectively.
  • HY-108900
    Leu-AMS
    Inhibitor 99.14%
    Leu-AMS (compound 6), a leucine analogue, is a potent inhibitor of leucyl-tRNA synthetase (LRS) with an IC50 of 22.34 nM, which inhibits the catalytic activity of LRS but did not affect the leucine-induced mTORC1 activation. Leu-AMS shows cytotoxicity in cancer cells and normal cells, and inhibits the growth of bacteria.
  • HY-136265
    BC-LI-0186
    Inhibitor
    BC-LI-0186 is a potent and selective inhibitor of Leucyl-tRNA synthetase (LRS; LeuRS) and Ras-related GTP-binding protein D (RagD) interaction (IC50=46.11 nM). BC-LI-0186 competitively binds to the RagD interacting site of LRS (Kd=42.1 nM) and has on effects on LRS-Vps34, LRS-EPRS, RagB-RagD association, mTORC1 complex formation or the activities of 12 kinases. BC-LI-0186 can effectively suppress the activity of cancer-associated MTOR mutants and the growth of rapamycin-resistant cancer cells. BC-LI-0186 is a promising agent for lung cancer research.
  • HY-108900A
    Leu-AMS R enantiomer
    Leu-AMS R enantiomer is the R enatiomer of Leu-AMS. Leu-AMS is a potent inhibitor of leucyl-tRNA synthetase (LRS) and inhibits the growth of bacteria.
  • HY-103280
    LysRs-IN-1
    Inhibitor
    LysRs-IN-1 is a Lysyl-tRNA synthetase (LysRs) inhibitor.
  • HY-112861
    Gln-AMS
    Inhibitor
    Gln-AMS is an aminoacyl-tRNA synthetases (AARS) inhibitor, which binds the A-domain within the NRPS enzymes.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.